There are 383 resources available
155TiP - Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Presenter: Suresh Ramalingam
Session: Poster Display session
156TiP - An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer
Presenter: Wei Zeng
Session: Poster Display session
158P - Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry
Presenter: Giannis Mountzios
Session: Poster Display session
159P - ReWARD study - Real world ALK resistance data: A single center experience
Presenter: Ullas Batra
Session: Poster Display session
163P - Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial
Presenter: Carminia Maria Della Corte
Session: Poster Display session
164P - Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients
Presenter: Luca Cantini
Session: Poster Display session
165P - Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first line immunotherapy-based regimens
Presenter: Giulia Mazzaschi
Session: Poster Display session
166P - Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients
Presenter: Shouzheng Wang
Session: Poster Display session
167P - KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Presenter: Laura Pinto
Session: Poster Display session